Search
Saredutant
go.drugbank.com/drugs/DB06660InvestigationalSaredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
SUVN-502
go.drugbank.com/drugs/DB06140Investigational’s and Schizophrenia, an unmet medical need. … SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer
Diaminopyrimidine oxide
go.drugbank.com/drugs/DB18756ApprovedDiaminopyrimidine oxide is a compound similar to [minoxidil] which is used to aid in hair growth.
Synonyms: 2,4-diaminopyrimidine 3-n-oxideIsoxicam
go.drugbank.com/drugs/DB08942ApprovedWithdrawnIsoxicam is a non-steroidal anti-inflammatory drug that is not marketed in the United States.
Bumadizone
go.drugbank.com/drugs/DB13286ApprovedBumadizone has been approved for use in Germany and Austria, it is a drug with anti-inflammatory, antipyretic, and analgesic properties, and was marketed for the treatment of both rheumatoid arthritis … Its use is restricted to these conditions, due to risks this drug poses [L5650].
NRP369
go.drugbank.com/drugs/DB06384ExperimentalNRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].
MEM 1003
go.drugbank.com/drugs/DB05547InvestigationalMEM 10003 was under investigation in clinical trial NCT00257673 (Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease) for the treatment of Alzheimer's Disease
Serinus canaria feather
go.drugbank.com/drugs/DB10857ApprovedCanary feather is used in allergenic testing.
Sampatrilat
go.drugbank.com/drugs/DB21283ExperimentalSampatrilat is a small molecule drug. Sampatrilat has a monoisotopic molecular weight of 584.25 Da.
Categories: Agents Acting on the Renin-Angiotensin SystemBZL101
go.drugbank.com/drugs/DB05051InvestigationalBZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.